HALO - Halozyme Therapeutics Non-GAAP EPS of $0.75 beats by $0.04 revenue of $216M in-line
2023-11-06 16:09:27 ET
- Halozyme Therapeutics press release ( NASDAQ: HALO ): Q3 Non-GAAP EPS of $0.75 beats by $0.04 .
- Revenue of $216M (+3.4% Y/Y) in-line.
- Sees 2023 Non-GAAP diluted earnings per share of $2.70 to $2.80.
- Sees 2023 EBITDA of $430 million to $445 million.
For further details see:
Halozyme Therapeutics Non-GAAP EPS of $0.75 beats by $0.04, revenue of $216M in-line